Ensysce Biosciences Inc (ENSC) Stock Price, Quote & News

Company Profile

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology. The company's lead product candidate is...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 263 4196

Website: www.ensysce.com

Address:

7946 Ivanhoe Avenue, Suite 201, La Jolla, United States

Sunnybhargava Sep. 11 at 8:04 PM

$ENSC no pr today. Stock was dry. Hopefully 🤞 next week. Still we holding good. July it was .23-.25.

1 · Reply

Bernic88 Sep. 11 at 7:46 PM

$ENSC I’m just doing a bit of trading and gambling here, but I hope for all the long-term investors that things eventually turn around and there isn't another reverse split🍀

0 · Reply

StockDreamin Sep. 11 at 7:18 PM

$ENSC g No data , no p r 's no dollar

0 · Reply

EnsysceBiosciences Sep. 11 at 7:16 PM

$ENSC We are advancing a broader approach to pain therapeutics, with programs addressing distinct challenges across severe and chronic pain. TAAP™ and MPAR® are designed around improving opioid safety, while CY200 brings a highly novel scientific approach to our pipeline as we expand into CRPS Type 1. These were among the key themes we brought together at PAINWeek 2026, reflecting how our pipeline is evolving across multiple areas of pain management. As Dr. Lynn Kirkpatrick summarized: “We also now have a groundbreaking Psilocybin CRPS therapy starting phase 2 soon. This approach could revolutionize care of this crippling disease.” $VRTX $SCLX

0 · Reply

EnsysceBiosciences Sep. 11 at 6:02 PM

PAINWeek gave us an opportunity to provide greater context around the highly novel scientific approaches to pain management now central to the $ENSC pain portfolio. A neural reset strategy brings a unique approach for patients with CRPS, while TAAP™ and MPAR® address important challenges associated with opioid treatment and patient safety. We look forward to sharing more highlights and key takeaways from the PAINWeek symposium soon.

0 · Reply

Sunnybhargava Sep. 11 at 5:20 PM

$ENSC they want to shake more. They need your shares. No one selling now. 🤷‍♂️👀

0 · Reply

Bernic88 Sep. 11 at 4:53 PM

$ENSC Don't worry, when the data comes out, we'll squeeze back to .52 😎

0 · Reply

StockDreamin Sep. 11 at 4:51 PM

$ENSC 49 is the new 49

1 · Reply

StockDreamin Sep. 11 at 3:32 PM

$ENSC another day no data, no pr, and not above 1$....but it was promised all week by the pumpmaster!

0 · Reply

Sunnybhargava Sep. 11 at 3:11 PM

$ENSC

0 · Reply

Ensysce Biosciences Announces Upcoming Conference and Industry Event Participation

2026-08-31T12:40:26.000Z - 13 days ago

Ensysce completes enrollment for final phase of PF614-MPAR-102 study

Aug 31, 2026, 8:30 AM EDT - 13 days ago

Ensysce Biosciences Completes Final Phase of PF614-MPAR-102 Clinical Study

Aug 20, 2026, 8:00 AM EDT - 24 days ago

Ensysce Biosciences to Showcase "A New Era in Pain Therapeutics" at PAINWeek 2026 Symposium

Aug 18, 2026, 11:00 AM EDT - 26 days ago

Ensysce Biosciences Transcript: Investor update

Aug 13, 2026, 4:15 PM EDT - 4 weeks ago

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

Ensysce Biosciences Earnings release: Q2 2026

Aug 13, 2026, 4:00 PM EDT - 4 weeks ago

Ensysce Biosciences Quarterly report: Q2 2026

2026-08-06T12:50:17.000Z - 5 weeks ago

Ensysce Biosciences completes acquisition of Cy Biopharma

Aug 6, 2026, 8:00 AM EDT - 5 weeks ago

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Aug 5, 2026, 9:00 AM EDT - 5 weeks ago

Ensysce Biosciences Slides: Investor presentation

2026-07-14T12:30:41.000Z - 2 months ago

Ensysce Biosciences awarded $5.3M installment in NIDA funding

Jul 14, 2026, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

2026-06-26T12:05:15.000Z - 2 months ago

Ensysce Biosciences enrolls first patient in final stage of PF614-MPAR-102

Jun 26, 2026, 8:00 AM EDT - 2 months ago

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

2026-06-04T20:45:12.000Z - 3 months ago

Ensysce Biosciences files to sell 1.3M shares of common stock for holders

Jun 4, 2026, 8:00 AM EDT - 3 months ago

Ensysce Biosciences Registration statement: Registration filing

May 15, 2026, 4:15 PM EDT - 4 months ago

Ensysce Biosciences Reports First Quarter 2026 Financial Results

May 15, 2026, 7:00 AM EDT - 4 months ago

Ensysce Biosciences Quarterly report: Q1 2026

May 15, 2026, 7:00 AM EDT - 4 months ago

Ensysce Biosciences Earnings release: Q1 2026

2026-05-12T15:40:41.000Z - 4 months ago

Ensysce announces expansion of patent protection for MPAR technology

May 12, 2026, 8:00 AM EDT - 4 months ago

Ensysce Biosciences Announces Expansion of Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

May 8, 2026, 8:00 AM EDT - 4 months ago

Ensysce Biosciences CEO Presents at Inaugural Clinical Pain Symposium in Amsterdam

Apr 20, 2026, 7:00 AM EDT - 4 months ago

Ensysce Biosciences Slides: Investor presentation

2026-04-16T13:08:30.000Z - 5 months ago

Ensysce secures IRB approval of final phase of PF614-MPAR-102 study

Apr 16, 2026, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study

Apr 9, 2026, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Registration statement: Registration filing

2026-04-09T10:12:51.000Z - 5 months ago

Ensysce Biosciences files to sell 20.34M shares of common stock for holders

2026-04-07T12:52:56.000Z - 5 months ago

Ensysce Biosciences secures second financing from 2025 agreement

Apr 7, 2026, 8:00 AM EDT - 5 months ago

Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs

Mar 30, 2026, 4:50 PM EDT - 5 months ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 30, 2026, 4:00 PM EDT - 5 months ago

Ensysce Biosciences Annual report: Q4 2025

Mar 30, 2026, 4:00 PM EDT - 5 months ago

Ensysce Biosciences Earnings release: Q4 2025

2026-03-04T13:51:12.000Z - 6 months ago

Ensysce Biosciences announces initiation of ‘Ask Me Anything’ series

Mar 4, 2026, 8:45 AM EST - 6 months ago

Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans

2026-03-03T13:32:48.000Z - 6 months ago

Ensysce Biosciences announces publication on MPAR technology

Mar 3, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology

2026-02-25T13:17:50.000Z - 6 months ago

Ensysce Biosciences initiates review of strategic alternatives

Feb 25, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value

Feb 23, 2026, 8:00 AM EST - 6 months ago

Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events

2026-01-28T13:26:39.000Z - 7 months ago

Ensysce Biosciences enrolls 50% of subjects in Phase 3 trial of PF614

Jan 28, 2026, 8:00 AM EST - 7 months ago

Ensysce Biosciences Provides Enrollment Update on Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid for Severe Acute Pain

2026-01-21T13:15:40.000Z - 7 months ago

Ensysce Biosciences expands global opioid patent portfolio

Jan 21, 2026, 8:00 AM EST - 7 months ago

Ensysce Biosciences Expands Global Opioid Patent Portfolio

2026-01-08T13:52:10.000Z - 8 months ago

Ensysce Biosciences receives EU patent for ADHD therapy

Jan 8, 2026, 8:00 AM EST - 8 months ago

Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection

Jan 7, 2026, 12:00 PM EST - 8 months ago

Ensysce Biosciences Transcript: AGM 2025

2026-01-05T14:30:53.000Z - 8 months ago

Ensysce Biosciences CEO says ‘positioned for continued momentum’

Jan 5, 2026, 8:00 AM EST - 8 months ago

Ensysce Biosciences Issues Annual Shareholder Letter

Dec 16, 2025, 7:00 AM EST - 9 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

Dec 12, 2025, 8:00 AM EST - 9 months ago

Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)

2025-12-09T13:25:51.000Z - 9 months ago

Ensysce Biosciences initiates enrollment in Phase 3 trial of PF614

Dec 9, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid

2025-12-02T22:00:54.000Z - 9 months ago

Ensysce Biosciences files to sell 4.6M shares of common stock for holders

2025-12-02T13:35:42.000Z - 9 months ago

Ensysce Biosciences issued notice of allowance for MPAR tech patent

Dec 2, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology

Dec 2, 2025, 7:00 AM EST - 9 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

Dec 2, 2025, 7:00 AM EST - 9 months ago

Ensysce Biosciences Registration statement: Registration Filing

Nov 21, 2025, 7:00 AM EST - 9 months ago

Ensysce Biosciences Proxy statement: Proxy Filing

2025-11-20T13:36:22.000Z - 9 months ago

Ensysce Biosciences receives FDA feedback on PF614 manufacturing

Nov 20, 2025, 8:00 AM EST - 9 months ago

Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach

Nov 17, 2025, 8:05 AM EST - 10 months ago

Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs

Nov 14, 2025, 4:15 PM EST - 10 months ago

Ensysce Biosciences Reports Third Quarter 2025 Financial Results

Nov 14, 2025, 4:00 PM EST - 10 months ago

Ensysce Biosciences Earnings release: Q3 2025

Nov 14, 2025, 4:00 PM EST - 10 months ago

Ensysce Biosciences Quarterly report: Q3 2025

Oct 10, 2025, 8:00 AM EDT - 11 months ago

Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025

Sep 4, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium

Aug 19, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025

Aug 14, 2025, 7:00 AM EDT - 1 year ago

Ensysce Biosciences Slides: Investor Presentation

Aug 13, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Quarterly report: Q2 2025

Aug 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Earnings release: Q2 2025

Jul 31, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback

Jul 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse

Jun 24, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2

Jun 11, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025

Jun 4, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection

May 13, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports First Quarter 2025 Financial Results

May 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Quarterly report: Q1 2025

May 13, 2025, 4:00 PM EDT - 1 year ago

Ensysce Biosciences Earnings release: Q1 2025

May 12, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Bolsters Management Team with Regulatory Expert

May 2, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Apr 24, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 4:41 PM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Apr 16, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Registration statement: Registration Filing

Apr 15, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces Positive Data from Opioid Overdose Protection Study

Mar 31, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences, Inc. Announces $1.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Ensysce Biosciences Announces PAINWeek 2025 Symposium and Recent Expert Panel Discussion on The State of the Nation in Pain

Mar 10, 2025, 4:15 PM EDT - 1 year ago

Ensysce Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Ensysce Biosciences Annual report: Q4 2024

Mar 10, 2025, 9:30 AM EDT - 1 year ago

Ensysce Biosciences Earnings release: Q4 2024

Mar 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences to Participate in the 37th Annual ROTH Conference

Mar 3, 2025, 9:43 AM EST - 1 year ago

Ensysce Biosciences CEO Dr. Lynn Kirkpatrick and Creighton University's Dr. Neel Pathak Discuss the Opioid Crisis and Next Generation Opioids

Feb 5, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Reports Continued Positive Progress in Groundbreaking Trial on PF614-MPAR, Comments on Current Landscape for Pain Treatment

Jan 22, 2025, 8:00 AM EST - 1 year ago

Ensysce Biosciences Announces Positive Interim Data for Breakthrough Therapy PF614-MPAR

Dec 23, 2024, 8:00 AM EST - 1 year ago

Ensysce Biosciences Regains Full Compliance with Nasdaq

Sunnybhargava Sep. 11 at 8:04 PM

$ENSC no pr today. Stock was dry. Hopefully 🤞 next week. Still we holding good. July it was .23-.25.

1 · Reply

Bernic88 Sep. 11 at 7:46 PM

$ENSC I’m just doing a bit of trading and gambling here, but I hope for all the long-term investors that things eventually turn around and there isn't another reverse split🍀

0 · Reply

StockDreamin Sep. 11 at 7:18 PM

$ENSC g No data , no p r 's no dollar

0 · Reply

EnsysceBiosciences Sep. 11 at 7:16 PM

0 · Reply

EnsysceBiosciences Sep. 11 at 6:02 PM

0 · Reply

Sunnybhargava Sep. 11 at 5:20 PM

$ENSC they want to shake more. They need your shares. No one selling now. 🤷‍♂️👀

0 · Reply

Bernic88 Sep. 11 at 4:53 PM

$ENSC Don't worry, when the data comes out, we'll squeeze back to .52 😎

0 · Reply

StockDreamin Sep. 11 at 4:51 PM

$ENSC 49 is the new 49

1 · Reply

StockDreamin Sep. 11 at 3:32 PM

$ENSC another day no data, no pr, and not above 1$....but it was promised all week by the pumpmaster!

0 · Reply

Sunnybhargava Sep. 11 at 3:11 PM

$ENSC

0 · Reply

patricius Sep. 11 at 3:07 PM

$ENSC WTH? Did someone forget to fuel this rocket 🚀 it should be on its way by now?

1 · Reply

BirchTreeJJ Sep. 11 at 2:32 PM

$ENSC friends. Quick heads up from me Easy double at TRUG from .53. Will be quick. Hurry.

0 · Reply

Bernic88 Sep. 11 at 2:24 PM

$ENSC Big day today? Is the data being transmitted by carrier pigeon—and it just needs another two years to arrive—or what’s supposed to happen today? Got a few "pumpers" around here, I see 😁

0 · Reply

Pelicanos Sep. 11 at 2:01 PM

$ENSC make the pain stop!

0 · Reply

Bernic88 Sep. 11 at 1:45 PM

$ENSC

0 · Reply

BirchTreeJJ Sep. 11 at 1:21 PM

$TRUG and $ENSC Are y’all ready to make some fortunes with me?

0 · Reply

cloverT Sep. 11 at 1:11 PM

$ENSC big day today!

1 · Reply

BirchTreeJJ Sep. 11 at 12:53 PM

$ENSC team also see $TRUG it’s a 500% mover from .50 coming quickly Good luck

0 · Reply

BirchTreeJJ Sep. 11 at 11:02 AM

$ENSC presentation in TWO hours from now 👀

0 · Reply

BirchTreeJJ Sep. 11 at 9:15 AM

$ENSC “if they need to” The dumbest response in history That’s the question! Hahaha With their recent acquisition they have enough money to get through 2027. They don’t need an offering. They need their price to come up. That’s what they need. That’s their focus. And will be.

0 · Reply

StockDreamin Sep. 11 at 3:08 AM

$ENSC more pain week Wednesday with upcoming Fed meeting...sure to tank the market!

0 · Reply

lifelearner Sep. 11 at 2:41 AM

$ENSC Do you think that post hints that they’re very unlikely to do a public offering, even if the share price skyrockets?

1 · Reply

Market Cap	9.47M
Revenue (ttm)	5.07M
Net Income (ttm)	-10.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-200.79%
Debt to Equity Ratio	0.00

Volume	562,900
Avg Vol	18,079,646
Day's Range	N/A - N/A
Shares Out	19.46M
Stochastic %K	74%
Beta	0.97
Analysts	Strong Buy
Price Target	$8.25